Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cardio Diagnostics Holdings, Inc.
Report date October 25, 2022 · Filed October 27, 2022
Section 16 reporting ended · disclosed 2022-10-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-25 transaction · row 1
1 source rowRow 1 · 2022-10-25 · Other · Disposed 1,565,000 · Balance 0 F1: Pursuant to the terms of the Subscription Agreement and the Second Amended and Restated Subscription Agreement and Letter Agreement between the Reporting Person and the Issuer (the "Agreements"), the Reporting Person transferred all of the common stock and private warrants it acquired in connection with the Issuer's initial public offering to permitted transferees with no consideration in compliance with the Agreements. |
| Private WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-10-25 | Direct | 0 |
Reported balance
After 2022-10-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-25 · Other · Disposed 2,500,000 · Balance 0 F1: Pursuant to the terms of the Subscription Agreement and the Second Amended and Restated Subscription Agreement and Letter Agreement between the Reporting Person and the Issuer (the "Agreements"), the Reporting Person transferred all of the common stock and private warrants it acquired in connection with the Issuer's initial public offering to permitted transferees with no consideration in compliance with the Agreements. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Subscription Agreement and the Second Amended and Restated Subscription Agreement and Letter Agreement between the Reporting Person and the Issuer (the "Agreements"), the Reporting Person transferred all of the common stock and private warrants it acquired in connection with the Issuer's initial public offering to permitted transferees with no consideration in compliance with the Agreements.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 25, 2022 Filed Oct 27, 2022 14:50 UTC | Cardio Diagnostics Holdings, Inc. CDIO · Entity 8239 | OtherPrivate Warrant · Derivative | 2,500,000 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001079973-22-001363 · ownership.xml · derivative · entry 2 Mana Capital LLC · CIK 0001896528 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500,000 shares Expires 2027-10-25 F1 · price: Pursuant to the terms of the Subscription Agreement and the Second Amended and Restated Subscription Agreement and Letter Agreement between the Reporting Person and the Issuer (the "Agreements"), the Reporting Person transferred all of the common stock and private warrants it acquired in connection with the Issuer's initial public offering to permitted transferees with no consideration in compliance with the Agreements. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 14:50 UTC | Cardio Diagnostics Holdings, Inc. CDIO · Entity 8239 | OtherCommon Stock, par value $0.00001 per share | 1,565,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001079973-22-001363 · ownership.xml · nonDerivative · entry 1 Mana Capital LLC · CIK 0001896528 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Subscription Agreement and the Second Amended and Restated Subscription Agreement and Letter Agreement between the Reporting Person and the Issuer (the "Agreements"), the Reporting Person transferred all of the common stock and private warrants it acquired in connection with the Issuer's initial public offering to permitted transferees with no consideration in compliance with the Agreements. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 19:59 UTC | Cardio Diagnostics Holdings, Inc. MAAQ · Entity 8239 | OtherCommon Stock, par value $0.00001 per share | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001079973-21-001187 · ownership.xml · nonDerivative · entry 1 Mana Capital LLC · CIK 0001896528 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,565,000 F1 · price: Pursuant to the terms of the Second Amended and Restated Subscription Agreement between the Reporting Person and the Issuer, the Reporting Person was issued a total of 75,000 shares of Common Stock in connection with the partial exercise by the underwriters of the over-allotment option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.